IVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry (IVTCC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04520347 |
Recruitment Status :
Enrolling by invitation
First Posted : August 20, 2020
Last Update Posted : April 1, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Ventricular Arrhythmia Ventricular Tachycardia Premature Ventricular Contraction (PVC) Cardiomyopathy |
Sudden cardiac death (SCD), predominantly due to ventricular tachyarrhythmias, is a leading cause of mortality in the United States and around the world. Catheter ablation of ventricular arrhythmias has proven efficacious in reducing the burden of arrhythmias and reducing implantable cardiac defibrillator (ICD) shocks.
The aim of this study is to create a prospective international database registry that will allow for better assessment of the outcomes of catheter ablation of ventricular arrhythmias. The registry, with approximately 30 participating centers, will help to identify the overall success rates and associated benefits of the procedure and provide more comprehensive data on understudied populations and treatment.
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 10000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 10 Years |
Official Title: | An International VT Ablation Center Collaborative Group (IVTCC): A Multicenter Ventricular Tachycardia Catheter Ablation Registry |
Actual Study Start Date : | December 1, 2018 |
Estimated Primary Completion Date : | December 2026 |
Estimated Study Completion Date : | November 2027 |

- Ventricular tachycardia (VT) recurrence [ Time Frame: From date of procedure assessed by shock, Anti-Tachycardia Pacing, or repeat procedure, up to 10 years. ]Freedom from ventricular tachycardia episodes requiring ICD Intervention (shock or Anti-Tachycardia Pacing) or repeat procedure.
- Rate of complications [ Time Frame: From date of procedure assessed up to 12 months. ]Cardiovascular-related and procedure-related major complications and/or adverse events.
- Time to transplant or death [ Time Frame: From date of procedure assessed by date of transplant and/or death, up to 10 years. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- All patients undergoing catheter ablation for ventricular tachycardia (VT) or premature ventricular contractions (PVCs).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04520347

Principal Investigator: | Jason Bradfield, MD | University of California, Los Angeles | |
Study Chair: | Kalyanam Shivkumar, MD, PhD | University of California, Los Angeles | |
Study Chair: | Paolo Della Bella, MD | San Raffaele Hospital, Italy | |
Study Chair: | Francis Marchlinski, MD, FACC, FAHA, FHRS | University of Pennsylvania Health System | |
Study Chair: | Andrea Natale, MD, FACC, FHRS, FESC | Texas Cardiac Arrhythmia Institute at St. David's Medical Center | |
Study Chair: | William G Stevenson, MD | Vanderbilt Heart and Vascular Institute |
Responsible Party: | Jason Bradfield, MD, Director, Specialized Program for Ventricular Tachycardia, University of California, Los Angeles |
ClinicalTrials.gov Identifier: | NCT04520347 |
Other Study ID Numbers: |
17-001725 |
First Posted: | August 20, 2020 Key Record Dates |
Last Update Posted: | April 1, 2021 |
Last Verified: | March 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Arrhythmia Cardiac Conduction System Disease Sudden Cardiac Death Implantable Cardiac Defibrillator (ICD) |
Cardiomyopathies Arrhythmias, Cardiac Tachycardia Tachycardia, Ventricular Ventricular Premature Complexes |
Heart Diseases Cardiovascular Diseases Pathologic Processes Cardiac Conduction System Disease Cardiac Complexes, Premature |